Compare TG Therapeutics Inc (TGTX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Verisign, Inc. — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Verisign, Inc. trades at $268.94 (market cap $25.26B). The key difference: Verisign, Inc. is far larger — about 3.1× TG Therapeutics Inc's market cap, and Verisign, Inc. pays a 1.17% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VRSN | |
|---|---|---|
Market Cap | $8.26B | $25.26B |
Sector | Health | Technology |
52-Week High | $59.06 | $310.00 |
52-Week Low | $26.39 | $211.49 |
Enterprise Value | $8.50B | $26.50B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VeriSign (VRSN) trades at $266.15, down 4.15% over the past day, with a mixed technical outlook showing bullish moving averages but overbought oscillators. The company maintains strong fundamentals with 2025 revenue of $1.66 billion, net income of $825.7 million, and a robust net income margin of 49.96%. Recent Q1 2026 earnings beat expectations with EPS of $2.34, while Q2 2026 results are anticipated. Analyst sentiment is predominantly positive with a 57% buy rating and a consensus price target of $325.25, suggesting significant upside potential.
The outlook for VRSN is cautiously optimistic, driven by its monopoly position in .com and .net domain registrations, consistent cash flow generation, and potential tailwinds from AI-driven domain growth. Key risks include contract renewal uncertainties, competitive pressures, and high valuation multiples. Investors should weigh the stock's premium valuation against its stable revenue streams and growth catalysts from digital expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
